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ABSTRACT  
Introduction 
Antimicrobial resistance (AMR) threatens successful Neisseria gonorrhoeae (NG) treatment, with few 
practical alternatives should ceftriaxone resistance become widespread. AMR point-of-care tests 
(AMR-POCTs), currently being developed, would allow selection of appropriate treatment regimens 
(including previously abandoned regimens), thereby sparing ceftriaxone use. We assessed cost-
effectiveness of five hypothetical AMR-POCT strategies (second antibiotic alongside ceftriaxone 
(Strategies A-C); single antibiotic alternative to ceftriaxone (Strategies D and E)) compared with 
Standard Care (SC; ceftriaxone and azithromycin dual-therapy), to inform appropriate 
implementation.  
Aim 
To assess the costs and effectiveness of these AMR-POCT strategies to optimise treatment regimen 
choice and reduce selection pressure on ceftriaxone. 
Methods  
Decision tree model simulating a cohort of 38,870 NG-diagnosed England sexual health clinic (SHC) 
attendees. AMR-POCT strategies and associated treatment options costed were: A) ciprofloxacin only 
(ciprofloxacin preferred over azithromycin as second agent if susceptible); B) azithromycin and 
ciprofloxacin (azithromycin preferred); C) ciprofloxacin and azithromycin (ciprofloxacin preferred); D) 
azithromycin AMR-POCT; E) ciprofloxacin AMR-POCT. A micro-costing approach, representing the cost 
to the SHC (for the year 2015/16), was employed. The time horizon was one year for initial patient 
treatment only. Primary outcomes were: total costs; percentage of people given optimal treatment 
(mono- or dual-therapy curing NG and not containing an antibiotic against which there was 
resistance); percentage of people given non-ceftriaxone optimal treatment; cost-effectiveness (cost 
per optimal treatment gained).  
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Results 
All AMR-POCT strategies cost more than SC. Strategy B avoided most sub-optimal treatments (n=48) 
but cost most to implement (£4,093,844 [5,474,656 EUR]). Strategy D was most cost-effective for both 
cost per optimal treatments gained (£414.67 [554.5 EUR] per optimal treatment gained) and 
ceftriaxone avoidance (£11.29 [15.10 EUR] per ceftriaxone-sparing treatment) but resulted in 
treatment failures (n=34) and sub-optimal treatments (n=706). 
Conclusions 
AMR-POCTs can enable correct antibiotic therapy at diagnosis and improved antibiotic stewardship, 
but may require net health-system investment. However, a relatively small reduction in test cost 
would enable monotherapy AMR-POCT strategies to be cost-saving. 
 
Key words: 
Neisseria gonorrhoeae; Sexually transmitted infection; antimicrobial resistance; point-of-care test; 
cost-effectiveness; ceftriaxone; ciprofloxacin; azithromycin  
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Introduction  
Antimicrobial resistance (AMR) has developed to every class of antibiotic used for treatment of the 
bacterial sexually transmitted infection (STI) Neisseria gonorrhoeae (NG) [1], with increasing reports 
of multi-drug resistant strains [2]. NG, the second most prevalent bacterial STI globally [3], is 
associated with serious long-term reproductive health complications if left untreated. 
World Health Organization (WHO) guidelines [4] recommend a treatment regimen that treats at least 
95% of circulating NG strains, as monitored through antibiotic surveillance programmes such as Public 
Health England’s national Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 
[1]. Dual-therapy with ceftriaxone and azithromycin is recommended in Europe [5], and was in the UK 
until 2019 [6] when it was replaced with 1g ceftriaxone monotherapy due to the emergence of 
azithromycin resistance [7]. AMR to ceftriaxone, an extended-spectrum cephalosporin, is the most 
urgent threat [8],[9] with few practical alternatives immediately available if widespread resistance 
develops.  
Rapid diagnostics have been identified as a key approach to tackling AMR [10]. Rapid tests are those 
that have a two-hour turnaround, whereas point-of-care tests (POCTs) enable test, results and 
treatment to be conducted in the same clinical visit [11]. A principal feature of an NG-AMR diagnostic 
is to assess antibiotic susceptibility at the time of NG diagnosis. A test that combines both NG diagnosis 
and AMR prediction at the point-of-care (AMR-POCTs) would allow the selection of appropriate 
treatment regimens for significant numbers of NG infections, including safe use of antimicrobials 
which have been abandoned for widespread use due to circulating resistance, but which would be 
effective for a significant proportion of infections [12]. For example, in the UK in 2018, 60% of NG 
infections were susceptible to ciprofloxacin, 90% to azithromycin and 88% to penicillin [1]. The ability 
to use these antibiotics to treat NG may in turn reduce AMR selection pressure on ceftriaxone [13]. 
Rapid tests are already being used for NG in some sexual health clinics (SHCs) [14]. While laboratory-
based NG fluoroquinolone susceptibility tests exist [15], rapid NG-AMR tests are in development and 
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being clinically evaluated, including an NG fluoroquinolone susceptibility AMR-POCT, developed 
within the Precise Study [16] using the io® platform (Binx Health Limited (formerly Atlas Genetics), 
Boston, USA), already CE-marked for Chlamydia trachomatis detection [12, 17]. Costs and short-term 
clinical impacts of these tests are used in procuring sexual health services provision for a region 
(known as sexual health commissioning in England) and adoption into SHCs’ decision-making [18]. 
In this analysis, we assessed the cost-effectiveness in English SHCs of five hypothetical AMR-POCT 
strategies for the treatment of NG, which enable use of ciprofloxacin and/or azithromycin, either 
alongside, or as an alternative to, ceftriaxone. Potential diagnostic resistance-determinants of these 
antibiotics are small in number (gyrA for ciprofloxacin; 23S rRNA and mtrCDE transporter for 
azithromycin), are relatively well-understood, and their absence predictive of susceptibility 
(particularly for ciprofloxacin). The development of molecular AMR-POCTs for detection of these 
determinants are thus technically feasible and therefore more likely to be immediately available [19-
21].  
Methods  
This report was written following the Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) checklist [22]. 
Model structure 
We compared Standard Care (SC) for NG treatment in the UK (at the time of investigation, ceftriaxone 
500mg and azithromycin 1g dual-therapy [6]) with five different AMR-POCT strategies (Supplementary 
Figure S1), where the AMR-POCT was used as a reflex test to inform antibiotic selection, irrespective 
of which test was used to diagnose NG initially. The AMR-POCT strategies were chosen to either 
facilitate optimised choice of a second antibiotic alongside ceftriaxone (dual-therapy), or enable a 
single antibiotic alternative to ceftriaxone (monotherapy) (Box 1).  
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The rationale for the monotherapy strategies is that an AMR-POCT enables effective treatment of the 
known resistance profile, sparing the use of ceftriaxone. The rationale for dual-therapy strategies is 
based on the assumption that combination therapy is more effective at preventing emergence or 
spread of AMR and thereby preserves the use of ceftriaxone [23].  
Each strategy consisted of a series of intended treatment regimens, contingent on the results of the 
AMR-POCT used. For example, in strategy B, the earliest intended treatment regimen was SC; where 
the AMR-POCT indicated azithromycin resistance, the second intended treatment regimen was 
ceftriaxone and ciprofloxacin; where the AMR-POCT then indicated ciprofloxacin resistance, the third 
intended treatment regimen was ceftriaxone monotherapy.  
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Box 1. Summary of AMR-POCT strategies 
Standard Care (SC) 
Standard care with dual-therapy of intramuscular ceftriaxone (500mg) and oral azithromycin (1g single dose).  
Dual-therapy, including ceftriaxone 
A) AMR-POCT for ciprofloxacin resistance only; infections identified as not resistant to ciprofloxacin are given oral ciprofloxacin (500mg) plus 
ceftriaxone (500mg). Infections identified as ciprofloxacin resistant are given SC.  
B) Dual AMR-POCT for azithromycin and ciprofloxacin resistance; if no azithromycin resistance is identified, SC is given. If azithromycin resistant, 
ciprofloxacin (500mg) and ceftriaxone (500mg) are given unless there is ciprofloxacin resistance, in which case ceftriaxone (500mg) is given alone.  
C) Dual AMR-POCT for ciprofloxacin and azithromycin resistance; if no ciprofloxacin resistance is identified, ciprofloxacin (500mg) and ceftriaxone 
(500mg) are given. If ciprofloxacin resistant, SC is given, unless there is also azithromycin resistance, when ceftriaxone (500mg) is given alone.  
Monotherapy optimisation 
D) AMR-POCT for azithromycin resistance: if no azithromycin resistance is identified, azithromycin (2g) is given. If azithromycin resistant, ceftriaxone 
(500mg) and ciprofloxacin (500mg) dual-therapy is given. If the AMR-POCT incorrectly shows no resistance (false negative for AMR), it is assumed the 
treatment fails. The treatment failure would be identified in the test-of-cure (TOC) and the patient would then receive 500mg ceftriaxone. 
E) AMR-POCT for ciprofloxacin; if no ciprofloxacin resistance is identified, 500mg ciprofloxacin monotherapy is given. If ciprofloxacin resistant, SC is 
given. If the AMR-POCT incorrectly shows no resistance, monotherapy is assumed to fail, the patient returns and receives 500mg ceftriaxone alone. 
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Strategy 
Antibiotic(s) for which 
resistance is tested Intended Treatment Regimen based on test result 
A   B 
No resistance to A Resistance to A 
Resistance to 
A + B 
Strategy A Ciprofloxacin     Ciprofloxacin + Ceftriaxone  Azithromycin + Ceftriaxone      
Strategy B Azithromycin + Ciprofloxacin Azithromycin + Ceftriaxone  Ciprofloxacin + Ceftriaxone  Ceftriaxone  
Strategy C Ciprofloxacin + Azithromycin Ciprofloxacin + Ceftriaxone  Azithromycin + Ceftriaxone  Ceftriaxone  
Strategy D Azithromycin     Azithromycina,b     Ciprofloxacin + Ceftriaxone    
Strategy E Ciprofloxacin     Ciprofloxacinb     Azithromycin + Ceftriaxone    
Standard 
Care 
No resistance testing is done. Standard Care (SC) is ceftriaxone 500mg and azithromycin 1g dual-therapy [6]  
 
                        
Unless otherwise stated, doses are: Ceftriaxone 500mg; Azithromycin 1g; Ciprofloxacin (500mg)         
Shaded areas indicate Standard Care (SC) i.e. azithromycin and ceftriaxone dual-therapy           
a2g dose given                     
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bIf incorrect test result and treatment fails, ceftriaxone is given               
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A decision tree model was constructed using TreeAge Pro (v.2017) to simulate a hypothetical cohort 
of 38,870 NG-diagnosed SHC attendees (21,915 men-who-have-sex-with-men [MSM], 8,488 women 
and 8,467 men-who-have-sex-with-women [MSW]), representing the total number of NG diagnoses 
in England SHCs in 2015, obtained from national surveillance data (GUMCAD) [24].  Our assumptions 
regarding AMR-POCT use meant the model could not be used when considering presumptive, e.g. for 
sexual contacts of NG-positive patients initially negative by microscopy but subsequently positive by 
NAAT testing. Approximately 10% of NG diagnoses are in contacts [25] but the epidemiological 
breakdown of these patients (e.g. women, MSW, MSM) and the nature of their NG diagnoses (e.g. 
microscopy negative and NAAT positive) is not reported. Therefore, contacts could not be removed 
from the hypothetical cohort. 
Key model assumptions include: 100% compliance with test protocols; all patients entering the model 
are NG true-positives; dual AMR-POCTs results are available simultaneously; there is no ceftriaxone 
resistance (supported by England’s national NG AMR sentinel surveillance system data [1]) so patients 
with monotherapy treatment failure would return and be successfully treated with ceftriaxone only. 
Model assumptions are provided in Supplementary Table S1. 
 
Outcomes  
We aimed to assess the costs and effectiveness of these AMR-POCT strategies to optimise treatment 
regimen choice and reduce selection pressure on ceftriaxone. The primary outcomes were the total 
costs (2015/16 GB £), the percentage of people given optimal treatment, and the percentage of people 
given non-ceftriaxone optimal treatment. ‘Optimal treatment’ was defined as one which cured NG 
and did not contain an antibiotic against which there was resistance. Model definitions are provided 
in Supplementary Table S2. These data were used to calculate incremental cost-effectiveness ratios 
(ICERs, see equation) for the cost per additional optimal treatment gained and the cost per additional 
ceftriaxone treatment avoided. This was chosen as the measure of cost-effectiveness rather than 
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other measures, such as cost per Quality Adjusted Life Years (QALYs), because little data exist on the 
consequence of optimal versus suboptimal NG treatment on long-term outcomes, such as mortality 
or lifetime costs.  
𝐼𝐶𝐸𝑅 =
𝐶𝑜𝑠𝑡𝐵 − 𝐶𝑜𝑠𝑡𝐴
𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠𝐵 − 𝐸𝑓𝑓𝑒𝑐𝑡𝑖𝑣𝑒𝑛𝑒𝑠𝑠𝐴
       
Secondary outcomes were the percentage of people given a ‘missed earlier intended treatment 
regimen’ (MEITR), and the percentage of people failing treatment due to resistance. ‘MEITR’ was 
defined as the use of a treatment regimen which cured NG, but where an earlier intended treatment 
regimen would have provided optimal treatment because susceptible infections had been 
misclassified as resistant by the AMR-POCT. MEITRs were independent of treatment effectiveness. 
Treatment 
AMR-POCT strategy treatment regimens were developed with input from three senior clinicians at St 
George’s University Hospitals NHS Foundation Trust, London, who outlined current and hypothetical 
AMR-POCT patient pathways (Supplementary Figure S1). The purpose of the work was to determine 
AMR-POCT strategy for short-term clinical impacts, because these are the data used for sexual health 
service provisioning and decision-making for adoption into SHCs [18]. Furthermore, progression to 
longer-term clinical impacts from suboptimally treated infection is poorly defined [26]. Therefore, the 
time horizon was that of initial patient treatment, and complications associated with STIs such as 
pelvic inflammatory disease (PID) in women, and adverse drug events associated with treatment, were 
not considered.  
Model parameters 
Model epidemiology parameters are presented in Table 1, and cost parameters in Table 2 and 
Supplementary Table S3. The hypothetical AMR-POCT sensitivity and specificity were based on other 
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NAAT-based rapid and POC tests [27-29], and altered in sensitivity analyses. Antibiotic resistance 
prevalences were obtained from national surveillance of SHC attendees (GRASP, 2017) [30]. GRASP is 
England’s national sentinel surveillance system that detects and monitors AMR in NG and records 
potential treatment failures. As the time horizon was that of initial patient treatment, discounting 
rates were not applied.
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Table 1. Epidemiology parameters used in the model 
Variable Percentage (%) Number  Comments, 
Reference MSM W MSW MSM W MSW 
Base 
case 
value 
Range 
(low, 
high) 
Base 
case 
value 
Range 
(low, 
high) 
Base 
case 
value 
Range 
(low, 
high) 
Base case 
value 
Range 
(low, 
high) 
Base 
case 
value 
Range 
(low, 
high) 
Base 
case 
value 
Range 
(low, 
high) 
1 Initial clinic 
attendances 
56.4 N/A 21.8 N/A 21.8 N/A 21,915  8,488  8,467  
GUMCAD, 2015 
[24] 
2 Resistance to 
azithromycina 
4.7  
3.3, 
6.1 
2.7  
1.9, 
3.5 
5.3  
3.7, 
6.9 
1,030 
723, 
1,337 
229 
161, 
297 
449 
313, 
584 
GRASP, 2017 [30] 
3 Resistance to 
ceftriaxone  
0.0  
0.0, 
0.0 
0.0  
0.0, 
0.0 
0.0  
0.0, 
0.0 
0 0, 0 0 0, 0 0 0, 0 
GRASP, 2017 [30] 
4 Resistance to 
ciprofloxacinb 
36.2  
25.3, 
47.1 
20.1  
14.1, 
26.1 
32.5  
22.8, 
42.3 
7,933 
5,544, 
10,322 
1,706 
1,197, 
2,215 
2,752 
1,930, 
3,582 
GRASP, 2017 [30] 
5 Sensitivity of AMR-
POCT 
98  
90, 
100 
98  
90, 
100 
98  
90, 
100 
N/A N/A N/A N/A N/A N/A 
Assumption  
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6 Specificity of AMR-
POCT 
99  
90, 
100 
99  
90, 
100 
99  
90, 
100 
N/A N/A N/A N/A N/A N/A 
Assumption 
MSM, men-who-have-sex-with-men; W, women; MSW, men-who-have-sex-with-women; N/A, Not Applicable; GUMCAD, genitourinary medicine clinical 
activity dataset; GRASP, gonococcal resistance to antimicrobial surveillance programme; AMR, antimicrobial resistance; POCT, point-of-care test. 
a  The azithromycin resistance ranges were extended further to 1-10% for all population groups in one way azithromycin resistance analysis so that the effect 
of more extreme values could be explored. 
b The ciprofloxacin resistance ranges were extended further to 0-50% in one way ciprofloxacin resistance analysis so that the effect of more extreme values 
could be explored 
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Table 2. Cost parameters used in the model 
Cost input  Costa  Comments and references  
Base case 
value 
Range (low, high) 
Management of 
NG (oral 
medication/IM 
injection)  
£53.00/£62.74 
70.88 
EUR/83.90 
EUR 
£37.1, £68.9 / £43.92, £81.56 
49.6, 92.1 EUR / 58.73, 
109.07 EUR 
bAdapted from previous 
model. Adams, 2014 [31] 
Return visit due to 
treatment failure 
£48.01 
64.20 EUR 
£33.61, £62.41 
44.95, 83.46 EUR 
b,c Adapted from previous 
model. Adams, 2014 [31] 
Single AMR-POCT  £29.00 
38.78 EUR 
£20, £40 
26.75, 53.49 EUR 
Estimate [32] 
Dual AMR-POCT  £31.90 
42.66 EUR 
 
£29, £58 
38.78, 77.56 EUR 
Estimate - 10% more than 
price of single AMR POCT 
(multiplier 1.1, range 1.0-2.0) 
Dual AMR-POCT £31.90 
42.66 EUR 
£22, £44 
29.42, 58.84 EUR 
Estimate – single AMR-POCT is 
varied, multiplier remains at 
1.1 (10% more than price of 
single AMR POCT) 
Azithromycin 1gd £1.16 
1.55 EUR 
£0.81, £1.51 
1.08, 2.02 EUR 
BNF, 2016 [33] 
Azithromycin 2gd £2.32 
3.10 EUR 
£1.62, £3.02 
2.17, 4.04 EUR 
BNF, 2016 [33] 
Ceftriaxone 
500mg e 
£9.58 
12.81 EUR 
£6.71, £12.45 
8.97, 16.65 EUR 
BNF, 2016 [33] 
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Ciprofloxacin 
500mgd 
£0.07 
0.09 EUR 
 
£0.05, £0.09 
0.07, 0.12 EUR 
BNF, 2016 [33] 
NG, Neisseria gonorrhoeae; IM, intramuscular; AMR, antimicrobial resistance; POCT, point-of-care 
test; BNF, British National Formulary. 
a GBP costs were converted to Euros using a historic currency conversion of an average of 366 days 
from the 1st July 2015 to 30th June January 2016 [34]. For this time period, 1 GBP = 1.34 Euros, and 1 
Euro = 0.75 GBP. 
b Includes staff time and consumables but not antibiotic costs. Costs were inflated to 2015/16 costs 
using the Hospital and Community Health Services (HCHS) Inflation Indices 2015 produced by the 
Personal Social Services Research Unit [35]. No data were available for inflation from 2014/15 to 
2015/16 so it was assumed to be the same as between 2013/2014 and 2014/15. The UK hospital 
consumer price index for health services shows similar annual growth in this sector from 2014 (93.2 
in 2013, 97.1 in 2014 and 100 in 2015), which validates this assumption [36]. GBP costs were converted 
to Euros using a historic currency conversion of an average of 366 days from the 1st July 2015 to 30th 
June January 2016 [34]. For this time period, 1 GBP = 1.34 Euros, and 1 Euro = 0.75 GBP. A further 
breakdown of cost data is provided in Supplementary Table S3. 
c Within the context of this model, treatment failure due to resistance to a monotherapy would result 
in a return visit. No repeat culture would be taken and no repeat diagnostic tests would occur. The 
patient would be successfully treated using ceftriaxone, administered via injection. 
d Oral medication.   
e Administered via intramuscular injection. The price quoted is for 1g vial of ceftriaxone, the smallest 
non-proprietary vial available (10) - the remaining 500mg is then discarded.  
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A micro-costing approach was employed, considering only costs incurred to the healthcare provider 
(i.e. SHC). Costs to those procuring sexual health services provision, or to health systems as a whole, 
were not considered. Costs were estimated by adapting an existing model [31], and included: 
laboratory equipment, POCTs and antibiotics, AMR-POCTs, NG treatment implementation (e.g. staff 
time and consumables, including partner notification and health promotion) (Supplementary Table 
S3). It was assumed the AMR-POCTs produced results in 30 minutes (maximum acceptable POCT run-
time for service users [37, 38]) and that in all strategies, NG-positive samples would still be sent to the 
laboratory for culture and phenotypic resistance testing. Costs are given in 2015/16 prices (GB £) and 
inflated when based on old estimates [35]. Antibiotic prices were extracted from the British National 
Formulary (BNF) website (September 2016), with the cheapest formulation being used including non-
proprietary costs where available [33]. Initial costs of diagnosing NG were not considered  as people 
only entered the model after an NG diagnosis. The cost of implementing a change to clinical practice 
was also not considered.  
Sensitivity analyses 
We conducted one-way analyses for each of the model parameters by varying them independently at 
the ends of their ranges to examine the effect on the primary outcome (Table 1). These analyses 
identified which model parameters results were most sensitive to. Each sensitivity analysis compared 
one of the five AMR-POCT strategies with SC, across three population groups (women, MSW, and 
MSM). Probabilistic sensitivity analyses were not performed because our analysis was a cost-
effectiveness analysis with the outcome as cost per event avoided, rather than a cost acceptability or 
cost utility analysis exploring the likelihood that the technology is cost-effective at different willingness 
to pay (WTP) thresholds. There is no commonly agreed WTP for our outcome, and therefore 
presenting PSA results would likely not have yielded additional beneficial information. 
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Results  
Overall AMR-POCT strategy costs, treatments used, and treatment outcomes compared with SC in all 
groups are presented in Table 3. Breakdowns by population group are presented in Supplementary 
Tables S4, S5 and S6.  
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Table 3. Total costs, treatments used and treatment outcomes for Standard Care and AMR-POCT strategies: all groups (n=38,870) 
Strategy Total cost a  Number of antibiotics used to treat NG Number of 
optimal 
treatmentsb  
Number of 
sub-optimal 
treatmentsc 
Number of 
MEITRd 
Number of 
treatment 
failurese 
Ceftriaxone Azithromycin Ciprofloxacin 
1. Standard care £2,856,168 
3,819,524 
EUR  
38,870 38,870 0 37,162 1,708 
- 
- 
A) Single POCT for 
ciprofloxacin; dual-therapy  
£3,954,554 
 5,288,385 
EUR 
38,870 12,408 26,462 38,057 813 265 - 
B) Dual POCT for azithromycin 
and ciprofloxacin; dual-
therapy 
£4,093,844 
 5,474,656 
EUR 
38,870 36,825 1,373 38,822 48 267 - 
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C) Dual POCT for ciprofloxacin 
and azithromycin; dual-
therapy 
£4,066,498 
5,438,086 
EUR 
38,870 11,736 26,462 38,611 259 912 - 
D) Single POCT for 
azithromycin; monotherapy  
£3,271,684 
 4,375,189 
EUR 
2,080 36,825 2,045 38,164 706 372 34 
E) Single POCT for ciprofloxacin; 
monotherapy 
£3,457,581 
4,623,788 
EUR  
12,656 12,408 26,462 38,057 813 265 248 
AMR, antimicrobial resistance; POCT, point-of-care test; NG, Neisseria gonorrhoeae; MEITR, missed earlier intended treatment regimen 
a GBP costs were converted to Euros using a historic currency conversion of an average of 366 days from the 1st July 2015 to 30th June January 2016 [34]. 
For this time period, 1 GBP = 1.34 Euros, and 1 Euro = 0.75 GBP. 
b‘optimal’ refers to a treatment regimen which cures the NG infection and does not contain any antibiotic against which there is resistance  
c‘sub-optimal’ refers to a treatment regimen which contains antibiotics against which there is NG resistance - if the treatment is a monotherapy it will result 
in treatment failure 
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d‘missed earlier intended treatment regimen’ (MEITR) refers to a treatment regimen which cures the NG infection and does not contain any antibiotic against 
which there is resistance, but a treatment regimen was used when an earlier intended treatment regimen would have provided optimal treatment – a MEITR 
is due to a false-resistant AMR-POCT result 
e‘treatment failure’ refers to failure to cure an NG infection due to resistance to an antibiotic given as monotherapy and is due to a false-susceptible AMR-
POCT result 
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Costs 
The cost of SC NG management was £2,856,168 (3,819,524 EUR) for the total cohort (Table 3). All 
AMR-POCT strategies cost more than SC, with dual-therapy AMR-POCT strategies more expensive than 
monotherapy strategies. Strategy D was the least expensive AMR-POCT strategy, costing £3,271,684 
(4,375,189 EUR), 14.5% more than SC. Strategy B was the most expensive, costing £4,093,844 
(5,474,656 EUR), 43% more than SC. This was consistent across all population groups. 
Optimal treatment 
All AMR-POCT strategies provided more optimal treatments than SC, in all population groups. Strategy 
B provided most optimal (n=38,822) and least sub-optimal (n=48) treatments. Strategies A and E 
equally provided the least optimal treatments (Supplementary Tables S4, S5 and S6) and the most sub-
optimal (n= 813) (Table 3). 
Ceftriaxone-sparing treatments given 
Since all dual-therapy strategies used ceftriaxone, only monotherapy strategies provided ceftriaxone-
sparing options. Strategy D reduced ceftriaxone use by 95% compared to SC (Table 3).  
MEITRs given 
A MEITR refers to a treatment regimen being used when an earlier intended treatment regimen would 
have provided optimal treatment. In all population groups, the fewest were in Strategies A and E 
(n=265), and B (n=267), and the most were in Strategy C (n=912) (Table 3, Supplementary Tables S4, 
S5 and S6). 
Treatment failures 
There were some treatment failures in each monotherapy strategy due to false-susceptible AMR-POCT 
results: strategy D had 34 (0.09% of treatments) and Strategy E had 248 (0.64% of treatments) (Table 
3). There were no treatment failures with SC or dual-therapy strategies (A, B and C) because they all 
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included ceftriaxone. This was consistent across all population groups (Supplementary Tables S4, S5 
and S6). 
Cost-effectiveness analysis (CEA) 
The cost-effectiveness analysis (CEA) results are presented in Table 4. When avoidance of sub-optimal 
treatments was considered, Strategy D was most cost-effective relative to SC, costing £414.67 (554.53 
EUR) per optimal treatment gained. Strategy A was least cost-effective overall, whereas Strategy B 
was the most-cost effective dual-therapy strategy.  
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Table 4. Cost effectiveness analysis (CEA) for SC and AMR-POCT strategies 
Sub-
group 
Comparison Total 
additional 
costa  
Additional 
cost per 
patienta 
Number of 
optimal 
treatments 
gained 
Additional cost per 
optimal treatment 
gaineda 
Number of 
ceftriaxone 
treatments 
avoided 
Additional cost per 
ceftriaxone-sparing 
treatment a 
All 
  
  
  
  
AMR-POCT A vs SC 
 £1,098,386 
1,468,860 
EUR 
£28.26 
37.79 EUR 
895 £1,226.97 
1,640.81 EUR 
0 
Dominated 
AMR-POCT B vs SC 
 £1,237,676 
1,655,131 
EUR  
£31.84 
42.58 EUR 
1,660 £745.44 
996.87 EUR 
0 
Dominated 
AMR-POCT C vs SC 
 £1,210,330 
1,618,562 
EUR  
£31.14 
41.64 EUR 
1,449 £835.39 
1,117.16 EUR 
 
0 
Dominated 
AMR-POCT D vs SC 
 £415,516 £10.69 
14.30 EUR 
1,002 £414.67 
554.53 EUR 
36,790  £11.29 
15.09 EUR 
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555,665.3 
EUR  
AMR-POCT E vs SC 
 £601,414 
804,264.8 
EUR  
£15.47 
20.69 EUR 
895 £671.82 
898.42 EUR 
26,214  £22.94 
30.68 EUR 
MSM 
  
  
  
  
AMR-POCT A vs SC 
 £620,274  
829,486.1 
EUR 
£28.30 
37.85 EUR 
499 £1,242.13 
1,661.09 EUR 
0 
Dominated 
AMR-POCT B vs SC 
 £697,730 
933,067.2 
EUR  
£31.84 
42.58 EUR 
1,001 £697.32 
932.52 EUR 
0 
Dominated 
AMR-POCT C vs SC 
 £683,317 
913,792.8 
EUR  
£31.18 
41.70 EUR 
864 £790.97 
1,057.76 EUR 
0 
Dominated 
AMR-POCT D vs SC 
 £235,532 £10.75 
14.38 EUR 
568 £414.38 
554.15 EUR 
20,676  £11.39 
15.23 EUR 
26 
 
314,974.5 
EUR  
AMR-POCT E vs SC 
 £358,920 
479,980 EUR  
£16.38 
21.90 EUR 
499 £718.75 
961.18 EUR 
13,842  £25.93 
34.68 EUR 
MSW 
  
  
  
  
AMR-POCT A vs SC 
 £239,316 
320,034.8 
EUR  
£28.26 
37.79 EUR 
248 £965.92 
1,291.72 EUR 0 
Dominated 
AMR-POCT B vs SC 
 £269,519 
360,425 EUR  
£31.83 
42.57 EUR 
436 £617.60 
825.91 EUR 
0 
Dominated 
AMR-POCT C vs SC 
 £263,674 
352,608.5 
EUR  
£31.14 
41.64 EUR 
391 £674.71 
902.28 EUR 0 
Dominated 
AMR-POCT D vs SC 
 £91,956 
122,971.8 
EUR  
£10.86 
14.52 EUR 
271 £339.59 
454.13 EUR 7,938 
 £11.58 
15.49 EUR 
AMR-POCT E vs SC  £132,108 £15.60 248 £533.21 5,658  £23.35 
27 
 
176,666.7 
EUR  
20.86 EUR 713.06 EUR 31.23 EUR 
Women 
  
  
  
  
AMR-POCT A vs SC 
 £238,796 
319,339.4 
EUR 
£28.13 
37.62 EUR 
148 £1,612.62 
2,156.54 EUR 
0 
Dominated 
AMR-POCT B vs SC 
 £270,428 
361,640.6 
EUR  
£31.86 
42.61 EUR 
223 £1,210.74 
1,619.11 EUR 
0 
Dominated 
AMR-POCT C vs SC 
 £263,339 
352,160.5 
EUR  
£31.02 
41.48 EUR 
194 £1,356.61 
1,814.18 EUR 
0 
Dominated 
AMR-POCT D vs SC 
 £88,028 
117,718.9 
EUR  
£10.37 
13.87 EUR 
163 £540.55 
722.87 EUR 
8,176  £10.77 
14.40 EUR 
AMR-POCT E vs SC 
 £110,386 £13.00 
17.38 EUR 
148 £745.45 
996.88 EUR 
6,714  £16.44 
21.99 EUR 
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147,618.1 
EUR  
AMR-POCT, antimicrobial resistance point-of-care test; MSM, men-who-have-sex-with-men; MSW, men-who-have-sex-with-women; SC, standard care. 
A strategy is ‘dominated’ if it is more expensive and provides fewer/equivalent benefits. 
a GBP costs were converted to Euros using a historic currency conversion of an average of 366 days from the 1st July 2015 to 30th June January 2016 [34]. 
For this time period, 1 GBP = 1.34 Euros, and 1 Euro = 0.75 GBP. 
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When avoidance of ceftriaxone use was considered, Strategy D was most cost-effective relative to SC, 
costing £11.29 (15.10 EUR) per ceftriaxone-sparing treatment gained. These findings were consistent 
across all population groups. 
Sensitivity analyses  
In one-way sensitivity analyses, the following four parameters had the greatest impact on cost-
effectiveness per optimal treatment gained for all AMR-POCT strategies and across all population 
groups: prevalence of azithromycin resistance; AMR-POCT sensitivity; prevalence of ciprofloxacin 
resistance; and the cost of single detection AMR-POCT. In monotherapy strategies, the cost-
effectiveness model was additionally sensitive to cost of clinical management (both with and without 
injection), cost of ceftriaxone, and AMR-POCT specificity (for strategy D). The cost multiplier for a dual 
detection AMR-POCT impacted on AMR-POCT cost-effectiveness for Strategies B and C. Tornado plots 
from these analyses are presented in Supplementary Figure S2. 
For all strategies, variation of ICER in relation to azithromycin resistance prevalence was minimal until 
prevalence fell to or below 3%, at which point it increased (Supplementary Figure S3). These rises in 
ICERs were least for strategies B and D. With the exception of strategy B where ICERs were consistent 
for all population groups, these increases in ICER were most limited in women.   
Variation in AMR-POCT accuracy also showed similar patterns across all population groups. Apart from 
Strategy D, variation in specificity had very little effect on cost per optimal treatment gained. In 
contrast, as sensitivity decreased to a minimum of 90%, particularly towards the lower range, the cost 
per optimal treatment gained increased exponentially, except for strategy B where the relationship 
was linear. Strategy B also had the smallest change in ICER between maximum (100%) and minimum 
(90%) sensitivity (maximum difference of £169.21 (226.28 EUR) per optimal treatment gained in 
women) compared with other strategies where the difference was in the thousands. For Strategy D, 
change in sensitivity had little impact on cost per optimal treatment gained, whereas when specificity 
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decreased to below around 95.5%,  the cost per optimal treatment gained started to increase 
exponentially. The sensitivity analyses are presented in Supplementary Figure S4. 
The prevalence of ciprofloxacin resistance had very little effect on cost per optimal treatment gained 
in Strategies B, C and D (Supplementary Figure S5). For Strategies A and E, as ciprofloxacin resistance 
increased from about 20%, there was an exponential increase in cost per optimal treatment gained 
for women only. 
The relationship between ICER and cost of a single target AMR-POCT was linear. Interestingly, as the 
cost of the single target AMR-POCT increased,  the two dual-target AMR-POCTs diverged, with strategy 
B costing less per optimal treatment gained relative to strategy C. 
For the three single target AMR-POCTs (A, D and E), reducing the cost of the test had the greatest 
impact on cost per treatment gained. Monotherapy strategies became cost-saving (ICER <0) for all 
population groups when AMR-POCT cost was ≤£18 (24.07 EUR) for Strategy D, and ≤£16 (21.40 EUR) 
for Strategy E (Supplementary Figure S6). Strategy B had lowest costs per additional optimal treatment 
for dual-therapy strategies. 
Discussion  
This is the first study to assess the cost-effectiveness and impacts of deploying AMR-POCTs for 
gonorrhoea. All AMR-POCT strategies assessed resulted in more optimal treatments compared with 
SC. Monotherapy AMR-POCT strategies provided ceftriaxone-sparing options, with Strategy D 
reducing the use of ceftriaxone by 95%. Both outcomes are important in promoting antibiotic 
stewardship by minimising risks of breakthrough with ceftriaxone-resistant circulating strains, and 
reducing selection pressure for resistance developing to ceftriaxone, respectively. 
Our cost-effectiveness analysis adapted a previously published cost-effectiveness model of 
introducing a dual CT/NG POCT into a SHC [29, 31], and was populated using available published data, 
and where unavailable, using unpublished data and expert opinion. By employing a decision tree 
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model approach we could account for sufficient complexity without over-building. This approach is, 
however, unable to assess outcomes that a transmission-dynamic model would be required for, such 
as that developed by Fingerhuth et al. [39], including impact AMR-POCTs could have on re-infection 
in a previously treated patient, on population prevalence or burden of disease, or on AMR evolution. 
Turner et al. have adapted the same CT/NG POCT cost-effectiveness model we used for our analysis 
[29, 31] to analyse the potential clinical and overall economic impact of an NG AMR-POCT [40]. Whilst 
theirs was not a cost-effectiveness analysis, and different model assumptions and parameters from 
ours were used, they also demonstrated that AMR-POCTs could lead to overall reductions in 
ceftriaxone use, but that introduction of AMR-POCTs incurred increased costs. Using an individual-
based dynamic transmission model that incorporated partner treatment and which was applied to a 
London MSM population, Zienkiewicz et al. [41] also demonstrated that AMR-POCTs for NG 
ciprofloxacin sensitivity reduced ceftriaxone use, by 70% compared with the reference scenario.  An 
individual-based model of molecular NG-AMR test-use compared with culture within an NG 
surveillance system in remote settings found that they substantially improve the timeliness of NG-
AMR detection, facilitating a faster change in recommended treatment, with potential for decreasing 
NG-AMR impact on the wider population [42]. Fingerhuth et al. [39] developed a compartmental 
transmission model of antibiotic-sensitive and antibiotic-resistant NG to look at proportion of resistant 
infections and cases averted. They showed that the clinical pathway that included an AMR-POCT 
resulted in the lowest proportion of resistant infections after 30 years, whereas the clinical pathway 
with a POCT that did not test for AMR resulted in the highest. They also noted that test diagnostic 
performance is key for AMR-POCTs to have a beneficial public health impact. The potential public 
health impact of AMR-POCTs was confirmed by Tuite et al., with AMR-POCTs delaying the proportion 
of isolates reaching >5% resistance compared with empiric treatment [43]. However, it was 
highlighted that the AMR-POCT must test for resistance to multiple anitimicrobials, otherwise non-
tested, resistant, strains will be selected for. Thus, continued surveillance, including culture, must be 
continued. Together, these health economic and modelling evaluations highlight the possible 
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beneficial impacts of implementing AMR-POCTs on reducing ceftriaxone use and decreasing NG-AMR 
prevalence at the population level, but the design and implementation of the tests should also be 
carefully considered.  
As with all mathematical models, several assumptions were made (Supplementary Table S1), including 
AMR-POCT diagnostic accuracy - a necessity as these tests are currently in early phases of 
development [16]. Future performance estimates will need to consider two elements: predictive 
accuracies of any biomarkers used to detect AMR; the performance of platforms and chemistries used 
to detect them. Variations in both may independently affect outcomes.  
Our analysis had some limitations. We used the most recent NG-AMR data available from GRASP at 
the time [30], but AMR rates constantly change and, in the sensitivity analyses, AMR prevalence 
alterations had the greatest impact on AMR-POCT cost-effectiveness (Supplementary Figure S2). This 
may limit the generalisability of our results, as it is not possible to know future resistance profiles. 
However, the results should be generalisable to the ranges used in the sensitivity analyses. In addition, 
as AMR-POCTs are still in development, some of the model’s other epidemiological parameters will 
have changed by the time the AMR-POCTs are available for use in routine practice, which may further 
limit the analyses’ applicability in the longer term. This highlights the need to continually conduct 
analyses such as these, to enhance our ability to predict and understand future trends. Our anlayses 
are also limited to data from England, with results perhaps less generalisable to other countries. This 
will be exacerbated by the 2019 change to 1g ceftriaxone monotherapy, further setting it aside from 
guidelines in other European countries [7]. Our model also did not consider NG-positive patients co-
infected with another organism, such as Chlamydia trachomatis, which would affect patient pathways 
and treatment options. Additional factors not considered were costs associated with treating long-
term NG infection sequelae [44], costs incurred outside of the SHC, and costs or cost-savings 
associated with changing clinical pathways in order to accommodate the AMR-POCTs. Thus the time 
horizon for the costs and consequences was of initial patient treatment only. 
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Strategy B was most effective for avoiding sub-optimal treatments but the most costly to implement. 
Strategy D was the most cost-effective for both effectiveness outcomes (optimal treatments gained 
and ceftriaxone avoidance), but resulted in treatment failures, as well as nearly 15-fold higher sub-
optimal treatments compared to Strategy B. Both strategies B and D enabled the re-use of 
ciprofloxacin, previously abandoned for the treatment of NG in the UK [6].  
All AMR-POCT strategies were more expensive than SC, with dual-therapy AMR-POCT strategies more 
expensive than monotherapy strategies, suggesting that short-term net financial investments in AMR-
POCT adoption are required to gain long-term antimicrobial stewardship benefits. Interestingly, our 
sensitivity analysis suggested that even if AMR-POCT costs were significantly reduced, perhaps 
through production scale-up, dual-therapy AMR-POCT strategies would still not be cost-saving. 
However, a relatively small reduction to <£18 (24.07 EUR) per test would enable the monotherapy 
AMR-POCT strategies to be cost-saving.   
The monotherapy strategies resulted in treatment failures due to false-susceptible AMR-POCT results, 
although minimal relative to SC. Since we assumed ceftriaxone treated 100% of NG infections, there 
were no treatment failures for SC or dual-therapy strategies. The most recent GRASP data suggest that 
ceftriaxone resistance remains low (no ceftriaxone resistance reported, although there is a reduction 
in susceptibility with 24.6% of isolates with minimum inhibitory concentrations (MICs) ≥0.03 mg/L in 
2018 compared with 16.6% in 2017 [1]), but there are increasing concerns regarding international 
ceftriaxone-resistant strains [45-47]. This potentially undermines our assumption and the resulting 
lack of treatment failures from dual-therapy AMR-POCT strategies. 
Most MEITRs (treatment regimen used when an earlier intended treatment regimen would have 
provided optimal treatment) were in Strategy C, and the least in Strategies A, B and E. Avoiding MEITRs 
is important because it maximises the ability to use ciprofloxacin (in Strategies A, C and E), or reduces 
the need for ceftriaxone use (Strategies B and D). These numbers were small compared to actual 
patient numbers in whom a MEITR might be used if these AMR-POCTs were available more generally. 
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For example, using national surveillance data [24, 48], we estimated that over 25,000 of the 38,870 
NG-diagnosed SHC patients assumed to have been treated with SC in 2015 would have had 
ciprofloxacin-susceptible NG. Strategies A and E would have enabled all, except 265 (Table 3), of these 
patients to be treated with ciprofloxacin, a 100-fold reduction in these missed opportunities.  
Since a MEITR is due to susceptible infections misclassified as resistant by the AMR-POCT, test 
specificity is key. In sensitivity analyses of AMR-POCT accuracy, Strategy D was the only strategy where 
cost per optimal treatment gained was affected by changes in specificity. In all other strategies, cost 
per optimal treatment gained increased as sensitivity decreased. This is because these strategies 
contained an AMR-POCT that included ciprofloxacin testing, so resistance (20-36%, dependent on 
population group [30]) was detected and optimal treatment could be given. In contrast, if AMR-POCT 
sensitivity in these strategies fell, true ciprofloxacin-resistant cases were missed and the patient sub-
optimally treated. Strategy D, where the AMR-POCT was for azithromycin only, was the only strategy 
where ciprofloxacin was given without resistance-testing - as the specificity decreased, more patients 
received false-positive azithromycin resistance results and were treated with ciprofloxacin. Due to 
high ciprofloxacin resistance prevalence, this treatment was sub-optimal in a large number of cases. 
Following the logic of the other strategies, if azithromyin resistance prevalence increased, cost per 
optimal treatment gained in Strategy D would become sensitive to both AMR-POCT specifity and 
sensitivity. 
Thus, prevalence of resistance has important implications for AMR-POCT accuracy requirements and 
ICERs of optimal treatments gained. In the azithromycin resistance sensitivity analyses, ICERs 
increased when resistance fell below about 3% (well below current UK azithromycin resistance 
prevalence, reported at approximately 9.7% [1]), primarily because when azithromycin resistance is 
low, there is little value in testing for it (Strategies B, C and D) and there will be few treatment failures 
from background resistance (Strategies A and E). In the ciprofloxacin resistance sensitivity analysis, an 
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effect on ICERs was only seen in women in strategies A and E (because of lower baseline ciprofloxacin 
resistance prevalence). 
From a population-level antimicrobial stewardship public health perspective, increasing the number 
of sub-optimal treatments may eventually lead to an increased number of resistant infections [39]. 
The relative public health importance of a smaller total number of sub-optimal treatments with a few 
treatment failures versus a higher number of sub-optimal treatments with no failures, warrants 
further investigation, and could be included in future transmission model analyses. Furthermore, the 
long-term public health impact of preserving ceftriaxone use whilst increasing the risk of treatment 
failures from monotherapy strategies (versus maintaining ceftriaxone in the earlier intended 
treatment regimen with an increase in sub-optimal treatments and no adequate treatment 
alternative), should also be investigated.  
Conclusion 
Once developed, AMR-POCTs could have wide-ranging implications for clinical decision-making 
globally, including the re-use of antibiotics previously abandoned for the treatment of NG, ensuring 
the right treatment is given to the right person, at the right time (precision medicine) [9, 12]. The 
O’Neill review of AMR [10] noted that accepting the initial expense of new test introduction may 
enable longer-term societal pay-offs by reducing infection rates and maintaining effective NG 
treatments. However, a relatively small reduction in test cost could enable some AMR-POCT strategies 
to be cost-saving.   
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